Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya shows positive long-term data in Crohn’s disease studies

智通财经2026/10/13 01:55

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to reports from Zhitong Finance APP, long-term data from two Phase 3 clinical trials conducted by Johnson & Johnson (JNJ.US) show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved clinical remission rates as high as 94% over three years.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya shows positive long-term data in Crohn’s disease studies

You may also like

Crypto prices